1. Introduction {#sec1-antioxidants-09-00304}
===============

Parkinson's disease (PD) represents the other common neurodegenerative disease after Alzheimer's disease (AD) \[[@B1-antioxidants-09-00304]\]. PD is characterized by tremor, rigidity, bradykinesia \[[@B2-antioxidants-09-00304]\], and postural instability \[[@B3-antioxidants-09-00304]\]. These symptoms are mainly attributed to the dopaminergic neurons depletion in the *substantia nigra pars compacta* \[[@B4-antioxidants-09-00304]\], leading to a subsequent loss of dopamine in the striatum \[[@B5-antioxidants-09-00304]\]. PD is accompanied by a presence of eosinophilic and intracytoplasmic inclusions called Lewy bodies \[[@B6-antioxidants-09-00304]\]. There is now considerable evidence showing that the degeneration also affects the cholinergic \[[@B7-antioxidants-09-00304]\], noradrenergic \[[@B1-antioxidants-09-00304]\], adrenergic, and serotoninergic systems \[[@B6-antioxidants-09-00304]\] resulting in non-motor symptoms namely sleep disorders \[[@B8-antioxidants-09-00304]\], cognitive problems ranging from memory impairment to dementia \[[@B7-antioxidants-09-00304]\], depression, anxiety, psychosis and apathy, all affecting patients life quality \[[@B9-antioxidants-09-00304]\].

With the high prevalence and the absence of treatment to curate PD \[[@B10-antioxidants-09-00304]\], several toxin models are provided to understand the pathogenesis and to develop new strategies against PD \[[@B11-antioxidants-09-00304]\]. Among the most recognized PD models, the 6-hydroxydopamine (6-OHDA), a neurotoxin inducing depletion of dopaminergic neurons in the *substantia nigra pars compacta* \[[@B12-antioxidants-09-00304]\]. It has experimented in cell cultures \[[@B13-antioxidants-09-00304]\] in rodents, in which the injection is localized in the medial forebrain bundle or other parts of the dopaminergic pathway \[[@B14-antioxidants-09-00304]\] and zebrafish \[[@B13-antioxidants-09-00304]\]. Used as a model organism of vertebrate development \[[@B15-antioxidants-09-00304]\], nowadays, zebrafish presents an encouraging model of neurodegenerative disorders such as AD, PD, Huntington disease, and schizophrenia \[[@B16-antioxidants-09-00304]\] due to its neuroanatomical and neurochemical pathways similitudes with the human \[[@B17-antioxidants-09-00304]\], and its high fecundity and short generation time allowing the evaluation of large drug varieties \[[@B13-antioxidants-09-00304]\].

Reactive oxygen species (ROS) are molecules generated during the normal cellular metabolism in aerobic life \[[@B18-antioxidants-09-00304]\] and containing one or more than an unpaired electron in one atomic orbital, giving them a high reactivity degree \[[@B19-antioxidants-09-00304]\]. The excess production of ROS, accompanied by the insufficient antioxidative defense, is described as oxidative stress \[[@B20-antioxidants-09-00304]\]. Numerous studies have shown that oxidative stress is correlated with the pathophysiology of PD \[[@B21-antioxidants-09-00304]\]. Indeed, the brain is more vulnerable to attacks from free radicals leading to neurodegeneration: on the one hand, the brain consumes more oxygen under physiological conditions, but then, it contains fewer amounts of endogenous antioxidant compounds \[[@B22-antioxidants-09-00304]\]. Many lines of evidence prove this hypothesis: the high amounts of ROS detected in particular brain areas \[[@B23-antioxidants-09-00304]\], the increased levels of free iron accumulated in the brain during PD \[[@B3-antioxidants-09-00304]\], and the presence of lipid peroxidation markers such as the 4-hydroxynonenal and malondialdehyde (MDA) in the *substantia nigra* of PD patients \[[@B19-antioxidants-09-00304]\]. Furthermore, the superoxide dismutase (SOD), catalase (CAT), peroxidase, and glutathione (GSH)---representing the endogenous antioxidative system---are found at lower levels in the *substantia nigra* of PD patients \[[@B24-antioxidants-09-00304]\].

Phenolic compounds are metabolites derived from L-phenylalanine \[[@B25-antioxidants-09-00304]\], including a large group of substances such as phenolic acids, hydroxycinnamic acids, lignans, tannins, and flavonoids \[[@B26-antioxidants-09-00304]\]. Phenolic compounds improve color, flavor, and food quality \[[@B27-antioxidants-09-00304]\]. They have shown beneficial effects on human health \[[@B28-antioxidants-09-00304]\], suggesting their use in pharmaceutical industries \[[@B29-antioxidants-09-00304]\]. Indeed, they possess antioxidant activity \[[@B30-antioxidants-09-00304]\], inhibiting, thus, ROS \[[@B31-antioxidants-09-00304]\], such as superoxide anion (O~2~^−^), hydroxyl radical (OH^−^), and hydrogen peroxide (H~2~O~2~) \[[@B32-antioxidants-09-00304]\], contributing to the prevention of several diseases including cancer, cardiovascular illnesses \[[@B27-antioxidants-09-00304]\] and neurodegenerative diseases \[[@B33-antioxidants-09-00304]\]. These natural compounds will constitute an alternative to the use of synthetic antioxidants (tertiary butyl hydroxy quinone (TBHQ), butylated hydroxyanisole (BHA), and propyl gallate (PG)), which have already shown carcinogenic effects \[[@B34-antioxidants-09-00304]\].

*Ceratonia siliqua* L. (*C. siliqua* L.) or carob, belongs to the family of Leguminosae \[[@B35-antioxidants-09-00304]\] and the sub-family of Caesalpinaceae \[[@B36-antioxidants-09-00304]\]. It is widespread in the Mediterranean basin \[[@B37-antioxidants-09-00304]\]. Carob is a perennial tree, evergreen \[[@B36-antioxidants-09-00304]\], dioecious with some hermaphrodite forms \[[@B27-antioxidants-09-00304]\]. *C. siliqua* L., naturally grown in arid regions \[[@B38-antioxidants-09-00304]\], and is a salinity and drought-resistant plant \[[@B27-antioxidants-09-00304],[@B35-antioxidants-09-00304]\]. In Morocco, it is distributed in the hems of the Atlas chains, in the Rif Mountains and in some southwestern valleys where the climate is arid and semiarid \[[@B39-antioxidants-09-00304]\]. *C. siliqua* L. is rich in A, B vitamins, insoluble fibers, sugar, and other minerals \[[@B38-antioxidants-09-00304],[@B40-antioxidants-09-00304]\]. *C. siliqua* L. is one of the most valuable plants as a source of gallic acid \[[@B41-antioxidants-09-00304]\], catechol, pyrogallol, and chlorogenic acid \[[@B42-antioxidants-09-00304]\]. Nowadays, economic gain \[[@B43-antioxidants-09-00304]\] has been experienced by various sectors such as industrial \[[@B34-antioxidants-09-00304]\], ornament \[[@B39-antioxidants-09-00304]\], cosmetics \[[@B37-antioxidants-09-00304]\], and health \[[@B28-antioxidants-09-00304]\]. Different parts of *C. siliqua* L. (leaf, flower, fruit, wood, bark, and root) are used in Moroccan pharmacopeia \[[@B43-antioxidants-09-00304]\]. There have been very few studies that have evaluated the antioxidant activity of leaves from this species \[[@B27-antioxidants-09-00304],[@B44-antioxidants-09-00304]\]. For this reason, the aqueous extract from *C. siliqua* L. (CsAE) leaves from southern Morocco was screened about its total phenolic, flavonoids, and condensed tannins contents. The *in vitro* antioxidant activity was measured through three tests: 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, ferric reducing power, and iron-chelating ability. Furthermore, the *in vitro* assay of acetylcholinesterase (AChE) inhibition was also carried out. The ultra-high-performance liquid chromatography (UHPLC) semiquantitative analysis was used to determine the main phenolic compounds from CsAE. In the second set of analyses, CsAE was also investigated for its eventual capacity to abolish anxiety, memory deficits, brain oxidative stress and to inhibit AChE in a 6-OHDA zebrafish model of PD.

2. Materials and Methods {#sec2-antioxidants-09-00304}
========================

2.1. Plant Material {#sec2dot1-antioxidants-09-00304}
-------------------

The leaves of *C. siliqua* L. were harvested in August 2017 from spontaneous trees in the south of Morocco (Tafraoute ). The collected samples were identified by Professor Mohamed Kadiri (Laboratory of Diversity and Conservation of Biological Systems, Department of Biology, Faculty of Science of Tetouan, Morocco). The samples were washed with tap water and distilled water, dried in the oven at 40 °C, and then ground using an electric grinder to obtain a powder, which was stored at 4 °C before analyses.

2.2. Extraction {#sec2dot2-antioxidants-09-00304}
---------------

CsAE was prepared according to Chen et al. \[[@B45-antioxidants-09-00304]\] with some modifications: 10 g of the plant powder was mixed with 500 mL of distilled water and incubated at 80 °C for 20 min; the mixture was centrifuged at 3000 rpm for 10 min at 25 °C. The supernatants were recovered and placed into the rotavapor. The dry matter yield was determined through the equation: DMY (%) = (Me/Mp) × 100, where DMY (%) = Dry matter yield, Me = Mass of the extract after the evaporation of the solvent and Mp = Mass of the plant used for the extraction. CsAE showed 93% of DMY.

2.3. Total Phenolic Content {#sec2dot3-antioxidants-09-00304}
---------------------------

The total phenolic content (TPC) of the CsAE was determined by the Folin--Ciocalteu method with some modifications \[[@B46-antioxidants-09-00304]\]: in a 96-well microtitre plate, 20 µL of diluted sample was mixed with 100 µL of Folin--Ciocalteu reagent (prepared by the mixture of 1 mL of Folin--Ciocalteu reagent and 9 mL of distilled water). After 4 min, 80 µL of saturated sodium carbonate solution (75 g/L) was added. After 30 min of incubation at room temperature, the absorbance at 765 nm was measured. Gallic acid hydrate at different concentrations was used as standard. TPC was estimated using the following linear equation: A = 0.191C−0.030; *R^2^* = 0.999, where A is the absorbance, C is the total phenolic content expressed as gallic acid equivalents (GAE) per dry weight (DW) of plant material (mg GAE/g DW).

2.4. Flavonoids Content {#sec2dot4-antioxidants-09-00304}
-----------------------

The flavonoids content (FC) was estimated using a 96-well microplate plate, following the aluminum chloride (AlCl~3~) method, with some modifications \[[@B18-antioxidants-09-00304]\]. Firstly, 10 µL of potassium acetate (1 M), then 80 µL of distilled water and finally 10 µL of AlCl~3~ (10%) were added to 25 µL of diluted extract or fraction and 75 µL of absolute methanol. The mixture was incubated in obscurity at room temperature for 30 min; the absorbance was measured at 415 nm using a spectrophotometer. Quercetin at different concentrations was used as the reference standard. FC was calculated using the linear equation: A = 0,150C−0.133; *R^2^* = 0.994 where A is the absorbance, C is the flavonoid content expressed as quercetin equivalents (QE) per dry weight (DW) of plant material (mg QE/g DW).

2.5. Condensed Tannins Content {#sec2dot5-antioxidants-09-00304}
------------------------------

The condensed tannins content (CTC) was estimated by the Folin--Denis method, according to Kusirisin et al. \[[@B47-antioxidants-09-00304]\], with some modifications. The reaction was carried out in a 96-well microplate reader. The mixture contained 15 µL of the sample, 25 µL of Folin--Denis reagent, 50 µL of Na~2~CO~3~ (0.5%) and 100 µL of distilled water. The mixture was vigorously stirred and then incubated at room temperature for 30 min. The absorbance was measured at 775 nm. The standard was prepared using different concentrations of tannic acid. Results were expressed as tannic acid equivalents (TAE) per dry weight (DW) of plant material (mg TAE/g DW) using the following equation: A = 0.180C−0.151; *R*^2^ = 0.992, where A is the absorbance and C is the condensed tannins concentration.

2.6. UHPLC Semiquantitative Analysis {#sec2dot6-antioxidants-09-00304}
------------------------------------

The sample analysis was performed using an UltiMate 3000 Thermo Fisher system, in a gradient of A (acetonitrile with 0.1% phosphoric acid) in B (0.1% phosphoric acid) as follows: 0--4 min. 10--15%, the next 4 min isocratic at 15%, 8--15 min 30%, 15--18 min 40%, 18--22 min 55%, then for the next 3 min, return to initial conditions. The column used for separation of the compounds was Luna Omega 5 µ Polar C18 (100A, 150 × 4.6 mm). The sample injection was 2 µL in a flow of 0.8 mL. Detection was assessed at seven different band wavelengths between 220 nm and 800 nm, taking into consideration 245 nm, 280 nm, 330 nm, and 521 nm; these four detection bands represent the maximum absorption bands for flavonoids, phenolic acids, and anthocyanidins respectively. Each peak was identified using the UV spectra and the library data available and was compared to the standards. Calibration curves were obtained for several standards (gallic acid, luteolin-7-O-glucoside, quercetin-3-β-glucoside, epicatechin, cyanidin-glucoside, rosmarinic acid), which were used for the quantification of the identified compounds.

2.7. Antioxidant Activity Assays {#sec2dot7-antioxidants-09-00304}
--------------------------------

The DPPH scavenging assay was evaluated according to Velazquez et al. \[[@B48-antioxidants-09-00304]\], with minor modifications using a 96-well microplate reader: 150 µL of DPPH^.^ solution (4 mg of DPPH diluted in 100 mL of absolute methanol) was incubated with 50 µL of the diluted sample at room temperature in obscurity for 30 min. Absorbance was then measured at 517 nm. The same procedure was repeated with ascorbic acid as the positive control. The negative control contained DPPH and methanol. The blank was the methanol.

Ferric reducing antioxidant power (FRAP) of extracts and fractions was evaluated via the test based on the capacity to reduce Fe^3+^ (FeCl~3~) to Fe^2+^ (FeCl~2~), according to Chahmi et al. \[[@B49-antioxidants-09-00304]\], with some modifications. Briefly, 125 µL of each sample was mixed with 313 µL of phosphate buffer sodium (0.2 M; pH 6.6) and 313 µL of K~3~Fe(CN)~6~ (1%). After 10 min of incubation at 50 °C, 313 µL of trichloroacetic acid (10%) was added, then 313 µL of distilled water and 66 µL of FeCl~3~ (0.1%). The absorbance was measured at 700 nm. The blank contained all the reagents except the sample, which was substituted by distilled water. Butylated hydroxytoluene (BHT) at different concentrations was used as standard.

The iron chelating activity of extracts and fractions was estimated using a 96-well microplate reader, via the protocol of Meghashri et al. \[[@B50-antioxidants-09-00304]\] with some modifications: 50 µL of the sample was mixed with 25 µL of FeCl~2~ (2 mM) and 58.3 µL of absolute methanol, the reaction was initiated with the addition of 25 µL of ferrozine (5 mM). The mixture was vigorously stirred and incubated at room temperature in obscurity for 10 min. The absorbance was measured at 562 nm. Absolute methanol was used as the blank of the reaction. The negative control was the reaction mixture except for the sample, which was substituted by methanol. The ethylenediaminetetraacetic acid (EDTA) was a positive control.

2.8. In Vitro Inhibition Assay of Acetylcholinesterase {#sec2dot8-antioxidants-09-00304}
------------------------------------------------------

The inhibition test of acetylcholinesterase (AChE) was determined through the Ellman's method with minor modifications \[[@B51-antioxidants-09-00304]\], 50µL of Tris--HCl buffer (50 mM; pH 8.0) added to 25 µL of acetylthiocholine iodide (ATCI) and 125µL DTNB (3 mM) and 10 µL of CsAE. All the reagents were mixed vigorously, then, 25 µL of AChE (0.25 U/mL). Absorbances were measured at 415 nm.

Results were expressed as the following equation: Inhibition (%) = A~control~ − A~sample~/A~control~.

Control is the mixture with methanol instead of the extract. Galanthamine hydrobromide was used as a positive control; it was tested at concentrations 15, 30, 60, 125, and 250 µg/mL.

All experiments were carried out in triplicate (*n* = 3); data are expressed as mean ± standard error. The IC~50~ values (the concentration of test compounds that inhibits hydrolysis of substrates by 50%) were determined by spectrophotometric measurement of the effect of increasing test compound concentrations (CsAE and galantamine hydrobromide) on AChE activity. The IC~50~ values were obtained from dose-effect curves by linear regression.

2.9. Animals {#sec2dot9-antioxidants-09-00304}
------------

Fifty adults zebrafish (*Danio rerio*) of wild-type short-fin strain (sex ratio: 50:50 male: female, 3-4-month-old, and 3--4 cm in length) purchased from an authorized commercial dealer (Pet Product S.R.L., Bucharest, Romania) was used in the present study. Fish were randomly divided into groups of 10 fish/24 L housing tanks filled with unchlorinated water, equipped with constant aeration and a light-dark cycle (14/10 h) photoperiod (lights on at 8:00 am). Water temperature within the tanks was maintained at 26 ± 1 °C; pH 7.5; dissolved oxygen at 7.20 mg/L; ammonium concentration \<0.004 ppm; conductivity 500 µS and filtrated to avoid the accumulation of organic toxins. Fish were fed twice daily with Norwin Norvitall flake (Norwin, Gadstrup, Denmark). For the behavioral studies, zebrafish were kept for 14 days to accommodate in laboratory conditions and then were divided into 5 groups: the control, the 6-hydroxydopamine (6-OHDA, 250 µM, Sigma-Aldrich, Darmstadt, Germany), and three CsAE treatment groups (0.1, 0.3, and 1 mg/L) administered in three consecutive steps, from 0 to 7 days. The doses of 6-OHDA and CsAE were chosen according to previous reports \[[@B52-antioxidants-09-00304],[@B53-antioxidants-09-00304]\]. CsAE (0.1, 0.3, and 1 mg/L) was individually delivered to fish through transferring into 500 mL glass for 1 h, once daily, whereas 6-OHDA (250 µM) treatment was once administered independently by moving into a 500 mL glass, one day before NTT test. Experimental protocol (as is summarized in [Figure 1](#antioxidants-09-00304-f001){ref-type="fig"}) was approved by the local board of ethics for animal experimentation (No. 15309/2019) and fully complied with the Directive 2010/63/EU of the European Parliament and of the Council of 22 September, 2010 on the protection of animals. Efforts were made to reduce animal suffering and the number of animals utilized.

2.10. Behavioral Analysis {#sec2dot10-antioxidants-09-00304}
-------------------------

### 2.10.1. Novel Tank Diving Test (NTT) {#sec2dot10dot1-antioxidants-09-00304}

The NTT is a specific test used for assessing anxiety in zebrafish, as described by Cachat et al. \[[@B54-antioxidants-09-00304]\]. The trapezoidal tank (1.5 L) used measured 15.2 height × 27.9 top × 22.5 bottom × 7.1 width cm, equally divided into two horizontal sections (top and bottom). After 1 h of CsAE treatment, the animals were placed individually within the test tank without acclimatization, and swimming behavior was recorded for 6 min. The animals were recorded with a Logitech HD Webcam C922 Pro Stream camera (Logitech, Lausanne, Switzerland) placed 30 cm away from the tank, and the videos were analyzed using ANY-Maze^®^ software (Stoelting CO, Wood Dale, IL, USA). The following parameters were registered: total distance in the tank (m) (to assess the locomotor activity), for the anxiety-like behavior: time spent in the top zone of the tank (s), and time spent in the bottom zone of the tank (s) were recorded. Representative tracking images of zebrafish locomotor activity from each group were obtained at the end of the analysis with ANY-Maze^®^ software. Imipramine (IMP, 20 mg/L, Sigma-Aldrich, Darmstadt, Germany) was used as the positive control in the NTT test.

### 2.10.2. Y-Maze Test {#sec2dot10dot2-antioxidants-09-00304}

Spatial memory in zebrafish was assessed using the Y-maze task \[[@B55-antioxidants-09-00304]\]. The apparatus consisted of a Y-maze glass aquarium with three arms (25 cm long, 8 cm wide and 15 cm high), filled with 3 L of the same water used in the home aquarium. After 1 h of CsAE treatment, each fish was tested individually during 5 min session. Donepezil (DP, 10 mg/L, Sigma-Aldrich, Darmstadt, Germany) was used as the positive control in the Y-maze test. The behavioral activity was analyzed using ANY-Maze^®^ software (Stoelting CO, Wood Dale, IL, USA) and with a Logitech HD Webcam C922 Pro Stream camera (Logitech, Lausanne, Switzerland) placed above the Y-maze tank. The following measures were recorded: the percent spontaneous alternation (to assess short-term spatial memory), and for the locomotory activity, the number of arm entries was recorded. Representative tracking images of zebrafish locomotor activity from each group were obtained at the end of the analysis with ANY-Maze^®^ software.

2.11. Biochemical Parameters Assay {#sec2dot11-antioxidants-09-00304}
----------------------------------

Immediately after behavioral tests, zebrafish were euthanized (10 min immersion in ice water, 2--4 °C) until loss of opercular motions \[[@B56-antioxidants-09-00304]\], and their whole brains were isolated for biochemical parameters assay. The brains were gently homogenized in ice 0.1 M potassium phosphate buffer (pH 7.4), 1.15% KCl with Potter Homogenizer (Cole-Parmer, Vermon Hills, IL, USA). The resulted homogenate was centrifuged at 960× *g* for 15 min. The supernatant was used for the estimation of acetylcholinesterase (AChE), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX) specific activities, and malondialdehyde (MDA) level, following the methods already described in detail by Dumitru et al. \[[@B55-antioxidants-09-00304]\]. Estimation of protein content was done through a bicinchoninic acid (BCA) protein assay kit (Sigma-Aldrich, Darmstadt, Germany) \[[@B57-antioxidants-09-00304]\].

2.12. Statistical Analysis {#sec2dot12-antioxidants-09-00304}
--------------------------

Results from three independent experiments are expressed as mean ± standard error of the mean (SEM). Results were statistically analyzed by one-way analysis of variance (ANOVA) followed by Tukey's *post hoc* multiple comparison test, considering treatment as a factor. The difference showing a *p* level of 0.05 or lower was considered statistically significant. GraphPad Prism 8.0 (GraphPad Software, Inc., San Diego, CA, USA) was used to perform statistical analyses. Correlation between the behavioral scores, enzymatic activities, and lipid peroxidation was estimated by the Pearson correlation coefficient (*r*).

3. Results and Discussion {#sec3-antioxidants-09-00304}
=========================

3.1. Total Phenolic Content {#sec3dot1-antioxidants-09-00304}
---------------------------

The highest amount of TPC was recorded in CsAE with 52.95 ± 0.141 mg GAE/g DW, which agrees with the study of Uysal et al. \[[@B58-antioxidants-09-00304]\], carried out on CsAE from Turkey. Thus, in the study of Hsouna et al. \[[@B40-antioxidants-09-00304]\], the TPC in *C. siliqua* leaf crude extract/water fraction was 130 ± 5.62 mg GAE/g. Moreover, the TPC in *C. siliqua* aqueous extract was 54.2 mg GAE/g DW, as obtained by Alali et al. \[[@B59-antioxidants-09-00304]\]. Othmen et al. \[[@B60-antioxidants-09-00304]\] reported quantities of 28.67 ± 0.09 g GAE/100 g DW *C. siliqua* leaf aqueous extract for TPC. In contrast, Aboura et al. \[[@B61-antioxidants-09-00304]\] reported that TPC of *C. siliqua* leaf infusion was 8.93 mg GAE/100 mL infusion. Based on these findings, CsAE exhibits a TPC comparable with those reported by other authors that assume its antioxidant and memory-facilitating activities.

3.2. Flavonoids Content {#sec3dot2-antioxidants-09-00304}
-----------------------

Supporting evidence suggested that the intake of flavonoids have been associated with health benefits such as antioxidant and anti-inflammatory effects, increased neuronal signaling, and improved metabolic functions \[[@B62-antioxidants-09-00304]\]. In our study, the value for FC from CsAE was 25.35 ± 0.124 mg QE/g DW. Othmen et al. \[[@B60-antioxidants-09-00304]\] reported value for *C. siliqua* leaf aqueous extract of 1.43 g rutin equivalents (RE)/100 g DW for FC. Sassi et al. \[[@B63-antioxidants-09-00304]\] reported that 1 mg of *C. siliqua* leaves aqueous extract contains 188 µg quercitin. Vaya and Mahmood \[[@B64-antioxidants-09-00304]\] reported that the leading free flavonoid was myricetin (340 mg/kg extract) from *C. siliqua* extract.

3.3. Condensed Tannins Content {#sec3dot3-antioxidants-09-00304}
------------------------------

Condensed tannins or proanthocyanidins have been demonstrated to prevent neuron damage, decrease brain oxidative stress and AChE, monoamine oxidase B, total nitric oxide synthase in senescent mice induced by D-galactose, and may be used to treat AD \[[@B65-antioxidants-09-00304],[@B66-antioxidants-09-00304]\].

In the present study, the value for CTC from CsAE was 11.43 ± 0.041 mg TAE/g DW. In a survey of Othmen et al. \[[@B60-antioxidants-09-00304]\], the condensed tannins content from *C. siliqua* leaf extracts reached 18.52 ± 0.03 g catechin equivalents (CE) 100/g DW. Highly polymerized condensed tannins containing a flavan nucleus were previously isolated from *C. siliqua* pods \[[@B67-antioxidants-09-00304]\].

3.4. UHPLC Analysis {#sec3dot4-antioxidants-09-00304}
-------------------

The registered chromatogram is indicated in [Figure 2](#antioxidants-09-00304-f002){ref-type="fig"} and shows the main peaks observed for the investigated *C. siliqua* sample at 280 nm, typical for flavonoids. The standard deviation values (expressed as %) varied between 0.06 and 0.18.

The major compound of the CsAE was luteolin-7-glucoside (23.78 w/w in the extract) followed by epicatechin (17.79 w/w in the extract), apigenin-7-glucoside (7.50 w/w in the extract), quercetin-3-glucoside (7.41 w/w in the extract), caffeic acid (4.84 w/w in the extract), gallic acid (4.54 w/w in the extract), and chlorogenic acid (3.59 w/w in the extract) ([Table 1](#antioxidants-09-00304-t001){ref-type="table"}).

The results indicate that flavonoids amount up to three times more than the phenolic acids and twice as the catechin. Moreover, such quantities indicate that *C. siliqua* leaves represent a good source of natural bioactive compounds. No aglycons were identified in our sample. Goulas and Georgiou \[[@B68-antioxidants-09-00304]\] demonstrated by HPLC analysis the presence of seven well-known phenolic antioxidants (gallic acid, syringic acid, catechin, epicatechin, quercetin, rutin, and myricetin) in the chemical composition of the carob extract. Among them, gallic acid was the main phenolic compound contained in the water extract. Moreover, significant amounts of rutin were noticed in the water extract, too. Corsi et al. \[[@B69-antioxidants-09-00304]\] reported the presence of gallic acid, (−) epigallocatechin-3-gallate, and (−) epicatechin-3-gallate in the pod and leaf of *C. siliqua* extracts by HPLC analysis.

3.5. Determination of Antioxidant Activity {#sec3dot5-antioxidants-09-00304}
------------------------------------------

The antioxidant activity of the *C. siliqua* aqueous extract is mainly linked to the phenolic compounds. Data from [Table 2](#antioxidants-09-00304-t002){ref-type="table"} reported the results of the antioxidant activities of CsAE using three methods: the capacity of scavenging DPPH radical, to reduce and to chelate iron.

CsAE showed high anti-DPPH activity with IC~50~ = 0.116 ± 0.002 mg/mL, a value that is near to that of ascorbic acid used as a reference drug. CsAE exhibited a high FRAP with an EC~50~ = 0.123 ± 0.003 mg/mL, which is slightly inferior to the BHT used as standard. CsAE showed a low ability to chelate iron 0.971 ± 0.006 mg/mL, while the EDTA showed the highest chelating ability with an IC~50~ of 0.117 ± 0.0005 mg/mL. We can deduce that the iron-chelating activity of CsAE was low compared with ferric reducing power and DPPH scavenging assay. Our results are in line with other studies that reported the antioxidant activity of *C. siliqua* extracts. The DPPH^.^ is a free radical relatively stable \[[@B32-antioxidants-09-00304],[@B70-antioxidants-09-00304]\] commonly used as an inexpensive, simple, and rapid test to estimate the capacity of extracts and active compounds to act as antioxidants by scavenging free radicals \[[@B71-antioxidants-09-00304]\]. Othmen et al. \[[@B59-antioxidants-09-00304]\] showed that both aqueous and ethanolic extracts of *C. siliqua* were able to trap free radicals. In contrast, the ethanolic extract presented the highest radical scavenging activity in terms of DPPH radicals, reaching 178.33 ± 2.12 g TE 100 g^−1^ DW. In another study, Goulas and Georgiou \[[@B66-antioxidants-09-00304]\] describe the antioxidant activity of the *C. siliqua* extracts, as evidenced by the DPPH IC~50~ radical scavenging activity (1.9 ± 0.2 mg/mL) and FRAP data (339.7 ± 4.0 mg FeSO4 100 g^−1^). As reported by Custódio et al. \[[@B72-antioxidants-09-00304]\], the methanolic extract of *Galhosa*, the female *C. siliqua* species from Spain, showed the highest DPPH scavenging power. According to the study carried out in Turkey, CsAE exhibited high DPPH inhibition percentage \[[@B58-antioxidants-09-00304]\]. The research conducted on the ethyl acetate fraction in Tunisia revealed a tremendous antioxidant activity demonstrated by a low IC~50~ value \[[@B40-antioxidants-09-00304]\]. Amessis-Ouchemoukh et al. \[[@B73-antioxidants-09-00304]\] have reported that the hydroethanolic extract of *C. siliqua* pods presented a high DPPH inhibition. The aqueous extract from three varieties of Algerian *C. siliqua* in the unripe stage also showed a high anti-DPPH capacity \[[@B74-antioxidants-09-00304]\]. The DPPH discoloration degree in a solution reveals the ability of extracts to release H^+^ protons \[[@B75-antioxidants-09-00304]\], and it is likely due to the presence of products having the capacity to interact with free radicals as electron donors \[[@B76-antioxidants-09-00304]\] and, therefore, inhibiting the ROS such the hydroxyl radical, superoxide anion \[[@B77-antioxidants-09-00304]\]. A dose-dependent relationship was observed between the concentration of CsAE and its antioxidant activity. DPPH scavenging capacity of plant extracts increases when the level of the OH^-^ groupings present in the aromatic rings rise \[[@B78-antioxidants-09-00304]\]. However, other non-phenolic compounds present in the extracts may have an antioxidant effect \[[@B79-antioxidants-09-00304]\].

CsAE showed an excellent capacity to reduce iron, significantly near to that of BHT. This result is hugely following the study of Benchikh et al. \[[@B74-antioxidants-09-00304]\], which have shown that aqueous extracts of three varieties ripe carob exhibited a high FRAP. As noted by Amessis-Ouchemoukh et al. \[[@B73-antioxidants-09-00304]\], the hydroethanolic extract of carob pods presented a great FRAP.

It was suggested that the chelation of transition metals presents one of the main strategies used to investigate the antioxidant activity of plant extracts \[[@B80-antioxidants-09-00304]\]. The presence of chelation factors allows the decrease of the red color of the ferrozine-Fe^2+^ complex in solution \[[@B81-antioxidants-09-00304],[@B82-antioxidants-09-00304]\]. Transition-metal ions play an essential role in the oxidation process via Fenton reaction \[[@B83-antioxidants-09-00304]\]; iron overload leads to the formation of lipid peroxidation products, which are involved in the onset of several chronic diseases \[[@B84-antioxidants-09-00304]\] especially neurodegenerative diseases \[[@B85-antioxidants-09-00304]\]. Therefore, iron chelators could be used as neuroprotective compounds against PD \[[@B86-antioxidants-09-00304]\]. In the current study, CsAE presented a moderate ability to chelate iron, which was significantly inferior to that of EDTA.

According to the study of El Hajaji et al. \[[@B44-antioxidants-09-00304]\], the methanolic extracts from a variety of Moroccan carob barks showed good antioxidant power *in vitro*. It was previously reported that three varieties of *C. siliqua* leaves from Morocco exhibited high antioxidant activity *in vitro* \[[@B27-antioxidants-09-00304]\]; from our results, we can deduce that CsAE could be used as a potential source of antioxidants. However, among 30 Moroccan medicinal plants, the CsAE from pods has not shown good antioxidant activity *in vitro* \[[@B87-antioxidants-09-00304]\]. The same result was reported in the study carried out on multitude types of *C. siliqua* pods extracts from Algeria \[[@B74-antioxidants-09-00304]\]. This difference could be explained by the fact that the antioxidant power of phenolic compounds is due to their high redox potential, which allows interacting as hydrogen donors, reducers, and singlet oxygen (^1^O~2~) quenchers \[[@B71-antioxidants-09-00304]\]. The structure of phenolic compounds is also involved in their antioxidant activity. Indeed, the presence of hydroxyls groupings in the aromatic rings of flavonoids at 3′, 4′, and 5′ position increases their antioxidant ability. In addition, phenolic compounds with two adjacent hydroxyl groupings can participate in the chelation process of transition metal ions such the iron and copper \[[@B88-antioxidants-09-00304]\].

3.6. Acetylcholinesterase Inhibitory Assay {#sec3dot6-antioxidants-09-00304}
------------------------------------------

As shown in [Figure 3](#antioxidants-09-00304-f003){ref-type="fig"}, CsAE exhibited anti-AChE activity in a dose-dependent manner. CsAE showed a high inhibitory activity against AChE with a maximal inhibition percentage of 88.53 ± 0.08 at 1 mg/mL of the extract and an IC~50~ value of 0.29 ± 0.004 mg/mL. The doses of 0.125 mg/mL (*p* \< 0.0001) and 0.5 mg/mL (*p* \< 0.001) of CsAE revealed a significant AChE inhibitory activity as compared to galantamine hydrobromide, a well-known AChE inhibitor, showing a maximal inhibition percentage of 98.05 ± 0.63 at 0.25 mg/mL and an IC~50~ value of 0.03 ± 0.0005 mg/mL. Our results agree with previous studies showing *in vitro* inhibitory activity on AChE of *C. siliqua* extract \[[@B34-antioxidants-09-00304]\]. Moreover, our group recently demonstrated that the methanolic extract of *C. siliqua* possessed *in vitro* potential inhibition of AChE \[[@B89-antioxidants-09-00304]\].

3.7. Effects on Anxiety-Like Behavior in NTT Test and on Spatial Memory in Y-Maze Test {#sec3dot7-antioxidants-09-00304}
--------------------------------------------------------------------------------------

[Figure 4](#antioxidants-09-00304-f004){ref-type="fig"} shows the results of 6-OHDA (250 µM) and CsAE (0.1, 0.3, and 1 mg/L) treatment of anxiety-like behavior within the NTT test. Representative locomotion tracking pattern ([Figure 4](#antioxidants-09-00304-f004){ref-type="fig"}A) highlighted the discrepancies between the top and bottom areas in swimming traces. It revealed that 6-OHDA-treated zebrafish exhibited a preference for the bottom zone, indicating an anxiogenic profile. Moreover, the 6-OHDA treatment increased the time spent in the bottom zone (*p* \< 0.01), as well as decreased the time spent in the top zone (*p* \< 0.001) as compared to the control group ([Figure 4](#antioxidants-09-00304-f004){ref-type="fig"}B). Reducing the time spent in the top zone of the tank suggests the anxiogenic-like profile of 6-OHDA. By decreasing the total distance traveled in the tank, 6-OHDA treatment created a hypolocomotor effect ([Figure 4](#antioxidants-09-00304-f004){ref-type="fig"}C) compared to control. By comparison, the time spent in the top zone of the tank ([Figure 4](#antioxidants-09-00304-f004){ref-type="fig"}B) indicates the anxiolytic-like result of CsAE, particularly at the dose of 0.3 mg/L. Besides, CsAE treatment avoids 6-OHDA anxiogenic effect as shown by decreasing of the time spent in the bottom zone of the tank (*p* \< 0.01 for 0.1 mg/L and *p* \< 0.0001 for 0.3 and 1 mg/L) ([Figure 4](#antioxidants-09-00304-f004){ref-type="fig"}B) and by increasing of the total distance travelled (*p* \< 0.0001 for 0.1 mg/L and *p* \< 0.001 for 0.3 and 1 mg/L) ([Figure 4](#antioxidants-09-00304-f004){ref-type="fig"}C) relative to 6-OHDA alone-treated zebrafish. Moreover, 6-OHDA alone-treated zebrafish exhibited a decreased total distance travelled in the tank as compared to the control group (*p* \< 0.0001), suggesting anxiogenic effects) ([Figure 4](#antioxidants-09-00304-f004){ref-type="fig"}C). IMP (20 mg/L) used as the positive reference drug exhibited an anxiolytic profile, as evidenced by decreasing the time spent in the bottom zone of the tank and by increasing the total distance travelled in the 6-OHDA-treated zebrafish.

[Figure 5](#antioxidants-09-00304-f005){ref-type="fig"} illustrates the effects of 6-OHDA (250 µM) and CsAE (0.1, 0.3, and 1 mg/L) treatment on the Y-maze spatial memory. Representative locomotion tracking pattern ([Figure 5](#antioxidants-09-00304-f005){ref-type="fig"}A) illustrates the differences between the Y-maze arms in swimming traces and shows that 6-OHDA treated group traveled less distance in the Y-maze, suggesting hypolocomotion. Moreover, the administration of 6-OHDA induced memory deficits as evidenced by decreased the percentage of spontaneous alternation (*p* \< 0.0001) ([Figure 5](#antioxidants-09-00304-f005){ref-type="fig"}B) as compared to the control group. Administration of CsAE significantly counters the 6-OHDA action induced-memory impairment, as evidenced by increased the percentage of spontaneous alternation in a dose-dependent manner. Reducing the percentage of spontaneous alternation suggests the memory impairment effect of 6-OHDA.

Furthermore, 6-OHDA administration affects locomotion, as illustrated by decreased number of arm entries (*p* \< 0.001) ([Figure 5](#antioxidants-09-00304-f005){ref-type="fig"}C) and a reduced of the total distance (*p* \< 0.0001) ([Figure 5](#antioxidants-09-00304-f005){ref-type="fig"}D) as compared to the control group. By contrast, the administration of CsAE in the 6-OHDA fish significantly improved locomotion, and increased total distance travelled in the Y-maze test. Our findings suggested that CsAE displayed anxiolytic and cognitive-enhancing effects, which could be attributed to the presence of the bioactive compounds shown in [Table 1](#antioxidants-09-00304-t001){ref-type="table"}. Recent studies have identified many physiological effects of *C. siliqua* fruit and its by-products due to the existence of bioactive compounds that may be important to the promotion of human health and chronic disease prevention \[[@B68-antioxidants-09-00304],[@B90-antioxidants-09-00304]\]. It has been demonstrated that *C. siliqua* is a source of bioactive ingredients with antioxidant, anti-hypertensive, and anti-inflammatory potential \[[@B91-antioxidants-09-00304]\]. Our results are in line with those reported by Alzoubi et al. \[[@B92-antioxidants-09-00304]\], who demonstrated that the methanolic extract from *C. siliqua* prevented short-term memory deficit induced by chronic stress in rats, probably as a result of avoiding reduction in the brain-derived neurotrophic factor (BDNF) levels in the hippocampus. Moreover, the CsAE exhibited an anxiolytic-like effect and prevented emotional behavior impairment and metabolic disorders induced by estrogen deficiency in rats \[[@B93-antioxidants-09-00304]\].

3.8. Effects on the Brain AChE Activity {#sec3dot8-antioxidants-09-00304}
---------------------------------------

The effect of CsAE on AChE activity in the zebrafish brain was examined. The 6-OHDA-treated zebrafish showed significantly increased AChE activity in the brain of zebrafish as compared to the control (*p* \< 0.001). By contrast, CsAE administration (0.1, 0.3, and 1 mg/L) significantly inhibited AChE in the brain by 6.49 ± 0.63 (*p* \< 0.001), 6.18 ± 0.51 (*p* \< 0.001), and 4.57 ± 0.49 (*p* \< 0.0001) nmol/min/mg protein compared with the 6-OHDA-treated group ([Figure 6](#antioxidants-09-00304-f006){ref-type="fig"}A).

AChE is an enzyme localized in the nervous system and muscles of vertebrates and humans \[[@B94-antioxidants-09-00304]\]. The significant role of this enzyme is the termination of transmission at the cholinergic synapses \[[@B95-antioxidants-09-00304]\] by hydrolyzing acetylcholine to choline and acetate \[[@B96-antioxidants-09-00304]\]. The inhibition of AChE could be used to treat AD \[[@B97-antioxidants-09-00304]\]. Moreover, the depletion of acetylcholine is also detected in PD, participating in dementia as a non-motor symptom of this pathology \[[@B98-antioxidants-09-00304]\]. Interestingly, alterations in the cortical cholinergic pathways can affect cognitive capacities and lead to dementia in PD patients \[[@B99-antioxidants-09-00304]\]. Several authors have shown that *C. siliqua*---mainly the leaves---exhibited an excellent ability *in vitro* to inhibit AChE \[[@B100-antioxidants-09-00304]\]. However, no studies were found about inhibition *in vivo*. In contrast, Uysal et al. \[[@B58-antioxidants-09-00304]\] showed that CsAE inhibited butyrylcholinesterase (BChE) but not inhibited AChE.

3.9. Effects on the Brain SOD, CAT, and GPX Specific Activities, and the MDA Level {#sec3dot9-antioxidants-09-00304}
----------------------------------------------------------------------------------

The 6-OHDA injection significantly decreased the SOD specific activity (*p* \< 0.001) ([Figure 6](#antioxidants-09-00304-f006){ref-type="fig"}B) in the zebrafish brain as compared to the control group, suggesting facilitation of the oxidative stress. The administration of CsAE in three doses (0.1; 0.3, and 1 mg/L) significantly prevented the decreased SOD activity in the 6-OHDA-treated zebrafish, but 0.1 mg/L remains the best ameliorative dose of SOD (*p* \< 0.00001) as compared to 6-OHDA alone-treated zebrafish. Our results also showed a significant decrease in CAT activity following the injection of 6-OHDA as compared to control (*p* \< 0.0001) ([Figure 6](#antioxidants-09-00304-f006){ref-type="fig"}C). The administration of the three doses of CsAE (0.1; 0.3, and 1 mg/L) in the 6-OHDA zebrafish significantly prevented the decrease of the same antioxidant enzyme, especially the dosage of 1 mg/L; however, the levels were inferior to those of control. We also observed that the 6-OHDA injection produced marked decreases in the activity of GPX (*p* \< 00001) ([Figure 6](#antioxidants-09-00304-f006){ref-type="fig"}D) and the three doses of CsAE significantly exhibited a high power to enhance the activity of GPX, especially the doses of 0.3 and 1 mg/L (*p* \< 0.00001) in zebrafish brain compared with 6-OHDA-treated zebrafish. The treatment with the 6-OHDA increases the levels of MDA in the zebrafish brain as compared to control (*p* \< 0.00001), and the administration of CsAE inhibits the MDA, especially with 1 mg/L ([Figure 6](#antioxidants-09-00304-f006){ref-type="fig"}E).

The brain is sensitive to oxidative stress, which activates the production of anion superoxide and hydrogen peroxide \[[@B101-antioxidants-09-00304]\]. ROS generated leads to neurons loss and, consequently, cognitive impairment observed in PD \[[@B21-antioxidants-09-00304]\]. The antioxidant enzymes such as SOD, CAT, and GPX play a vital role in the human body's defense against oxidative stress \[[@B102-antioxidants-09-00304]\]. The SOD is a metalloenzyme, ubiquitous \[[@B103-antioxidants-09-00304]\], and having the capacity to scavenge the superoxide radical \[[@B104-antioxidants-09-00304]\]; this enzyme catalyzes the dismutation of superoxide anion into molecular oxygen (O~2~) and hydrogen peroxide (H~2~O~2~) \[[@B105-antioxidants-09-00304]\]. The GPX belongs to the family of isozymes using GSH to reduce H~2~O~2~ and lipid hydroperoxides \[[@B103-antioxidants-09-00304]\]. CAT is the essential detoxification enzyme; it is indispensable for the direct dismutation of H~2~O~2~ into H~2~O and O~2~ \[[@B103-antioxidants-09-00304]\]. MDA is the main marker of lipid peroxidation \[[@B102-antioxidants-09-00304]\]; it is a reactive aldehyde resulting from the peroxidation of polyunsaturated fatty acids in the cells membrane \[[@B106-antioxidants-09-00304]\].

The study of Akkaya and Yilmaz \[[@B107-antioxidants-09-00304]\] pointed out that the methanolic extract of *C. siliqua* from Turkey has a good capacity to reduce MDA levels *in vitro*. Corsi et al. \[[@B69-antioxidants-09-00304]\] suggested that the CsAE from Italy had a strong inhibition power of T1 cell proliferation. In addition, the CsAE from pods from Tunisia exerted a high antioxidant capacity in the kidney, liver and brain of adult male Wistar rats \[[@B108-antioxidants-09-00304]\]. Rtibi et al. \[[@B109-antioxidants-09-00304]\] found that the CsAE from pods exhibited *in vivo* antioxidant activity in ethanol-treated male swiss albino mice and male Wistar rats. Moreover, pretreatment of male albino Wistar rats with the ethyl acetate fraction from the *C. siliqua* leaves from Tunisia prevented oxidative damages induced by carbon tetrachloride (CCl~4~) in the kidney and liver \[[@B40-antioxidants-09-00304]\]. Additionally, the ethanolic extract from *C. siliqua* leaves was found to be effective in protecting against oxidative damage induced by cisplatin in the kidney of albino male mice \[[@B110-antioxidants-09-00304]\].

Pearson correlation coefficient (*r*) was used to test the linear association between memory scores, antioxidant enzymes, and lipid peroxidation ([Figure 7](#antioxidants-09-00304-f007){ref-type="fig"}). Significant negative correlations between the spontaneous alternation percentage vs. MDA (*n* = 10, *r* = −0.730, *p* \< 0.0001) ([Figure 7](#antioxidants-09-00304-f007){ref-type="fig"}A) and between the total distance travelled in the tank vs. MDA (*n* = 10, *r* = −0.621, *p* \< 0.0001) ([Figure 7](#antioxidants-09-00304-f007){ref-type="fig"}B) were observed. The negative value of *r* indicates that the improvement of memory scores in specific tests such as Y-maze and NTT is well correlated with a decreased level of MDA, a marker of lipid peroxidation. Moreover, strong positive correlation was noticed by linear regression between AChE vs. MDA (*n* = 10, *r* = 0.901, *p* \< 0.0001) ([Figure 7](#antioxidants-09-00304-f007){ref-type="fig"}C). However, significant negative correlations between CAT vs. MDA (*n* = 10, *r* = −0.940, *p* \< 0.0001) ([Figure 6](#antioxidants-09-00304-f006){ref-type="fig"}D) and between GPX vs. MDA (*n* = 10, *r* = −0.873, *p* \< 0.0001) ([Figure 7](#antioxidants-09-00304-f007){ref-type="fig"}E) were reported when linear regression was calculated. In this case, the positive and negative values of the *r* indicate that decreasing of AChE specific activity as well as increasing of CAT and GPX specific activities is well correlated with a low MDA level. Custodio et al. \[[@B100-antioxidants-09-00304]\] reported a correlation between in vitro antioxidant activity and the inhibitory activity on α-amylase, α-glucosidase, AChE, and BChE following the administration of the *C. siliqua* extract. Using the *r* determination, we have shown that improving memory performance in 6-OHDA-treated zebrafish is linked to increased antioxidant enzyme activity along with a decreased AChE activity and the level of MDA (lipid peroxidation), which promotes the CsAE neuroprotective profile.

4. Conclusions {#sec4-antioxidants-09-00304}
==============

By using UHPLC analysis, we showed that the major compound of the CsAE was luteolin-7-glucoside, followed by epicatechin, apigenin-7-glucoside, quercetin-3-glucoside, caffeic acid, gallic acid, and chlorogenic acid. Furthermore, the obtained data accomplished the proposed objectives, showing that CsAE attenuated memory deficits and anxiety resulting from 6-OHDA treatment by a mechanism implying restoring of brain antioxidant status and regulation of AChE activity. Consequently, the present study indicated that CsAE could be regarded as an alternative source of bioactive compounds that could enhance memory processes in the 6-OHDA zebrafish model of PD.
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![Schematic representation of the experimental protocol.](antioxidants-09-00304-g001){#antioxidants-09-00304-f001}

![The ultra-high-performance liquid chromatography (UHPLC) chromatogram of the aqueous extract of *C. siliqua* (CsAE) indicating the picks following: 1. Gallic acid; 2. Epicatechin; 3. Chlorogenic acid; 4. Caffeic acid; 5. Quercetin-3-glucoside; 6. Luteolin-7-glucoside; 7. Apigenin-7-glucoside (numbers refer to [Table 1](#antioxidants-09-00304-t001){ref-type="table"}).](antioxidants-09-00304-g002){#antioxidants-09-00304-f002}

![Inhibition percentages of acetylcholinesterase (AChE) exhibited by different concentrations of CsAE (0.0625--1 mg/mL) and galantamine hydrobromide (0.015--0.25 mg/mL). Coefficient and Regression equation of inhibition displayed by CsAE: *y* = 21.398*x* − 61.181, *R^2^* = 0.9972, IC~50~ = 0.29 ± 0.004 mg/mL. Coefficient and Regression equation of inhibition displayed by galantamine hydrobromide: *y* = 14.406*x* + 17.386, *R^2^* =0.9985, IC~50~ = 0.03 ± 0.0005 mg/mL.](antioxidants-09-00304-g003){#antioxidants-09-00304-f003}

![*Ceratonia siliqua* aqueous extract (CsAE, 0.1, 0.3, and 1 mg/L) ameliorated locomotion pattern and reduced anxiety in the NTT test. (**A**) Representative locomotion tracking pattern of the control, 6-hydroxydopamine (6-OHDA) (250 µM), CsAE (0.1, 0.3, and 1 mg/L), and imipramine (IMP) (20 mg/L) treated groups. (**B**) Represent the time spent in the top/bottom zone by zebrafish in the tank in different groups. (**C**) Represent the total distance travelled by zebrafish in the tank in different groups. Values are means ± S.E.M. (*n* = 10). For Tukey's *post hoc* analyses: (**B**) Control vs. 6-OHDA (250 µM): \#\#*p* \< 0.001, 6-OHDA (250 µM) vs. CsAE (0.1 mg/L): \# *p* \< 0.01, 6-OHDA (250 µM) vs. CsAE (0.3 mg/L): \#\#\# *p* \< 0.0001 and 6-OHDA (250 µM) vs. CsAE (1 mg/L): \#\#\# *p* \< 0.0001; (**C**) Control vs. 6-OHDA (250 µM): \#\#\# *p* \< 0.0001, 6-OHDA (250 µM) vs. CsAE (0.1 mg/L): \#\#\#p \< 0.0001, 6-OHDA (250 µM) vs. CsAE (0.3 mg/L): \#\# *p* \< 0.001 and 6-OHDA (250 µM) vs. CsAE (1 mg/L): \#\# *p* \< 0.001.](antioxidants-09-00304-g004){#antioxidants-09-00304-f004}

![*Ceratonia siliqua* aqueous extract (CsAE, 0.1, 0.3, and 1 mg/L) improved locomotion pattern and memory in the Y-maze test. (**A**) Representative locomotion tracking of the control, 6-OHDA (250 µM) CsAE (0.1, 0.3, and 1 mg/L), and donepezil (DP) (10 mg/L) treated groups. (**B**) Represent the percentage of spontaneous alternation in the Y-maze in different groups. (**C**) Represent the number of arm entries in the Y-maze in different groups. (**D**) Represent the total distance travelled by zebrafish in the Y-maze in different groups. Values are means ± S.E.M. (*n* = 10). For Tukey's *post hoc* analyses: (**B**) Control vs. 6-OHDA (250 μM): \#\#\#*p* \< 0.0001, 6-OHDA (250 µM) vs. CsAE (0.1 mg/L): \#\# *p* \< 0.001, 6-OHDA (250 µM) vs. CsAE (0.3 mg/L): \#\#\# *p* \< 0.0001 and 6-OHDA (250 µM) vs. CsAE (1 mg/L): \#\#\#\# *p* \< 0.00001; (**C**) Control vs. 6-OHDA (250 μM): \#\# *p* \< 0.001, 6-OHDA (250 µM) vs. CsAE (0.1 mg/L): \# *p* \< 0.01, 6-OHDA (250 µM) vs. CsAE (0.3 mg/L): \#\# *p* \< 0.001 and 6-OHDA (250 µM) vs. CsAE (1 mg/L): \#\#\# *p* \< 0.0001; (**D**) Control vs. 6-OHDA (250 μM): \#\#\# *p* \< 0.0001, 6-OHDA (250 µM) vs. CsAE (0.3 mg/L): \#\#\# *p* \< 0.0001 and 6-OHDA (250 µM) vs. CsAE (1 mg/L): \#\#\# *p* \< 0.0001.](antioxidants-09-00304-g005){#antioxidants-09-00304-f005}

![*Ceratonia siliqua* aqueous extract (CsAE, 0.1, 0.3, and 1 mg/L) exhibited an anti-AChE effect and improved brain antioxidant status. The enzyme's specific activities: (**A**) Acetylcholinesterase (AChE), (**B**) Superoxide dismutase (SOD), (**C**) Catalase (CAT), and (**D**) Glutathione peroxidase (GPX) and (**E**) Malondialdehyde (MDA) level. Values are means ± S.E.M. (*n* = 10). For Tukey's *post hoc* analyses: (**A**) Control vs. 6-OHDA (250 μM): \#\#*p* \< 0.001, 6-OHDA (250 µM) vs. CsAE (0.1 mg/L): \#\# *p* \< 0.001, 6-OHDA (250 µM) vs. CsAE (0.3 mg/L): \#\# *p* \< 0.001 and 6-OHDA (250 µM) vs. CsAE (1 mg/L): \#\#\#\# *p* \< 0.0001; (**B**) Control vs. 6-OHDA (250 μM): \#\# *p* \< 0.001, 6-OHDA (250 µM) vs. CsAE (0.1 mg/L): \#\#\#\# *p* \< 0.00001, 6-OHDA (250 µM) vs. CsAE (0.3 mg/L): \#\#\# *p* \< 0.0001 and 6-OHDA (250 µM) vs. CsAE (1 mg/L): \#\# *p* \< 0.001; (**C**) Control vs. 6-OHDA (250 μM): \#\#\# *p* \< 0.0001, 6-OHDA (250 µM) vs. CsAE (0.1 mg/L): \# *p* \< 0.01, 6-OHDA (250 µM) vs. CsAE (0.3 mg/L): \# *p* \< 0.01 and 6-OHDA (250 µM) vs. CsAE (1 mg/L): \#\# *p* \< 0.001; (**D**) Control vs. 6-OHDA (250 μM): \#\#\#\# *p* \< 0.00001, 6-OHDA (250 µM) vs. CsAE (0.1 mg/L): \#\#\# *p* \< 0.0001, 6-OHDA (250 µM) vs. CsAE (0.3 mg/L): \#\#\# *p* \< 0.0001 and 6-OHDA (250 µM) vs. CsAE (1 mg/L): \#\#\#\# *p* \< 0.00001; and (**E**) Control vs. 6-OHDA (250 μM): \#\#\#\# *p* \< 0.00001, 6-OHDA (250 µM) vs. CsAE (0.1 mg/L): \#\# *p* \< 0.001, 6-OHDA (250 µM) vs. CsAE (0.3 mg/L): \#\# *p* \< 0.001 and 6-OHDA (250 µM) vs. CsAE (1 mg/L): \#\#\# *p* \< 0.0001.](antioxidants-09-00304-g006){#antioxidants-09-00304-f006}

![Correlation analyses between behavioral and biochemical parameters (Pearson's correlation, *n* = 10): (**A**) spontaneous alternation% vs. MDA: *r* = −0.730, *p* \< 0.0001; (**B**) total distance travelled vs. MDA: r = −0.621, *p* \< 0.0001; (**C**) AChE vs. MDA: *r* = 0.901, *p* \< 0.0001; (**D**) CAT vs. MDA: *r* = −0.940, *p* \< 0.0001 and (**E**) GPX vs. MDA: *r* = −0.873, *p* \< 0.0001. Data expressed are spontaneous alternation %, total distance travelled (m), AChE (nmol/min/mg protein), CAT (U/mg protein), GPX (U/mg protein), and MDA (nmol/mg protein).](antioxidants-09-00304-g007){#antioxidants-09-00304-f007}

antioxidants-09-00304-t001_Table 1

###### 

The most important compounds identified in *C. siliqua* aqueous extract by UHPLC analysis.

  ---------------------------------------------------------------------------
  Sample   Compound\                                                   
           (w/w in the Extract)                                        
  -------- ---------------------- ------- ------ ------ ------ ------- ------
  CsAE     4.54                   17.79   3.59   4.84   7.41   23.78   7.50

  ---------------------------------------------------------------------------

1\. Gallic acid; 2. Epicatechin; 3. Chlorogenic acid; 4. Caffeic acid; 5. Quercetin-3-glucoside; 6. Luteolin-7-glucoside; 7. Apigenin-7-glucoside.

antioxidants-09-00304-t002_Table 2

###### 

Antioxidant activities of the *C. siliqua* aqueous extract and standards.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antioxidant\                                                IC~50~ (mg/mL)   Coefficient and Regression Equation   Maximal Inhibition Percentages (%)                                   
  Activity\                                                                                                                                                                               
  Assays                                                                                                                                                                                  
  ----------------------------------------------------------- ---------------- ------------------------------------- ------------------------------------ --------------- --------------- ----------------
  1,1-Diphenyl-2-picrylhydrazyl **(**DPPH) scavenging power   CsAE             Ascorbic acid                         CsAE                                 Ascorbic acid   CsAE            Ascorbic acid\
                                                                                                                                                                                          (1 mg/mL)

  0.116 ± 0.002                                               0.106 ± 0.0005   *y* = −10.929*x* + 97.105\            *y* = 15.48*x*−12.535\               84.65 ± 0.01    92.14 ± 0.04    
                                                                               *R^2^* = 0.9948                       *R^2^* = 0.9915                                                      

  Ferric reducing antioxidant power **(**FRAP)                CsAE (EC~50~)    BHT (EC~50~)                          CsAE                                 BHT             CsAE            BHT

  0.123 ± 0.003                                               0.118 ± 0.00     *y* = −0.101*x* + 0.915\              *y* = 0.311*x* − 0.017\              \-              \-              
                                                                               *R^2^* = 0.9999                       *R^2^* = 0.9958                                                      

  Iron chelating activity                                     CsAE             EDTA                                  CsAE                                 EDTA            CsAE            EDTA\
                                                                                                                                                                                          (1 mg/mL)

  0.971 ± 0.006                                               0.117 ± 0.0005   *y* = −12.356*x* + 62.71\             *y* = 15.927*x* − 12.002\            51.5 ± 0.02     94.96 ± 0.003   
                                                                               *R^2^* = 0.9939                       *R^2^* = 0.9914                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The half maximal inhibitory concentration (IC~50~) and the half maximal effective concentration (EC~50~) of the *C. siliqua* aqueous extract (CsAE) were compared with those of the standards: There is no significant difference between CsAE and standards. Butylated hydroxytoluene (BHT), Ethylenediaminetetraacetic acid (EDTA).

[^1]: These authors contributed equally to this work.
